Entities / Company
MaxCyte (United States).
Biotech company in Rockville, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 26
What's happening
Gone quiet
No new reports in 90+ days-
PHC Corporation signed an exclusive agreement with MaxCyte to distribute its platform in Japan, with operations launched in Singapore.Speculative1 report
-
MaxCyte is utilizing LinkedIn for professional following, while Kristen White works for Oak Street Communications.Speculative1 report
-
MaxCyte provided its platform technology to Anocca AB, which will use the technology for manufacturing.Some support1 report
-
TG Therapeutics signed an SPL agreement with MaxCyte on August 7, 2025.Some support1 report
-
MaxCyte (United States) underperformed the market so far this year, based on data from August 7, 2025.Some support1 report
-
MaxCyte licensed its platform technology to Adicet Bio, Inc. for cell therapies, amid reports that Trump-era tariffs benefit AI stocks.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around MaxCyte (United States) this week
News at the entities that move MaxCyte (United States) most-
SPL StructuralJD.com and SPL have collaborated to launch a B2B platform supporting businesses in Saudi Arabia.Moves MaxCyte (United States)
Connections
The 1 strongest of 26, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SPL Structural
MaxCyte's growth is dependent on the revenue streams and opportunities provided by SPL.
History
Events by the month they beganJune 2026
6 events- PHC Corporation signed an exclusive agreement with MaxCyte to distribute its platform in Japan, with operations launched in Singapore.
- MaxCyte is utilizing LinkedIn for professional following, while Kristen White works for Oak Street Communications.
- MaxCyte provided its platform technology to Anocca AB, which will use the technology for manufacturing.
- TG Therapeutics signed an SPL agreement with MaxCyte on August 7, 2025.
- MaxCyte (United States) underperformed the market so far this year, based on data from August 7, 2025.
- MaxCyte licensed its platform technology to Adicet Bio, Inc. for cell therapies, amid reports that Trump-era tariffs benefit AI stocks.